English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
中國抗體SM17針對治療哮喘疾病的新藥研究申請獲國家藥監局批准
Aug 14, 2023 21:11 HKT
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP
Aug 14, 2023 21:10 HKT
四环医药「创新药+医美」双轮驱动战略成效显著
Aug 07, 2023 19:16 HKT
四環醫藥「創新藥+醫美」雙輪驅動戰略成效顯著
Aug 07, 2023 19:15 HKT
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology
Aug 01, 2023 20:14 HKT
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology
Aug 01, 2023 20:00 HKT
沛嘉医疗启动TaurusTrio反流瓣膜 内地多中心注册临床研究首日入组成功完成
Aug 01, 2023 16:47 HKT
沛嘉醫療啟動TaurusTrio反流瓣膜 內地多中心註冊臨床研究首日入組成功完成
Aug 01, 2023 16:46 HKT
Exploring New Collaborative Opportunities! The Indonesia-China Healthcare and Biotech Investment Forum Successfully Held
Jul 31, 2023 19:48 HKT
Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients
Jul 28, 2023 06:00 HKT
亿胜生物宣布贝伐珠单抗眼科适应症I/II期临床研究成功完成
Jul 26, 2023 19:00 HKT
億勝生物宣布貝伐珠單抗眼科適應症I/II期臨床研究成功完成
Jul 26, 2023 18:59 HKT
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Jul 26, 2023 18:58 HKT
BioGX Candida Auris PCR Assay Global Adoption Accelerates
Jul 25, 2023 00:00 HKT
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
Jul 24, 2023 20:19 HKT
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
Jul 24, 2023 19:30 HKT
沛嘉医疗公布2023年上半年度未经审核营运数据
Jul 21, 2023 20:52 HKT
沛嘉醫療公佈2023年上半年度未經審核營運數據
Jul 21, 2023 20:51 HKT
Peijia Medical Announces its Unaudited Operating Statistics for the First Half of 2023
Jul 21, 2023 20:50 HKT
ADC国际化潜力受捧 科伦博泰或享龙头估值溢价
Jul 20, 2023 20:13 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: